Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
NCT03842254Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erythropoietin in autoimmune hepatitis (AIH), sponsored by Northwestern University. Primary endpoint: Change in number of regulatory T cells at 12 weeks. Started Jan 2019; status: completed.
02
Drugs
erythropoietin
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT03842254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842254.